Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
NEW YORK, April 18, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") (NASDAQ:AKRX) between March 1, 2017 and February 26, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Illinois. To get more information go to:
http://www.zlk.com/pslra-d/akorn-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’ acquisition of the Company; (2) the Company lacked effective internal controls over financial reporting; and (3) as a result, the Company’s financial statements were materially false and misleading at all relevant times.
If you suffered a loss in Akorn you have until May 7, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
